Graffe CC, Bech JN, Pedersen EB. Effect of high and low sodium intake on urinary aquaporin-2 excretion in healthy humans. Am J Physiol Renal Physiol 302: F264 -F275, 2012. First published October 12, 2011 doi:10.1152/ajprenal.00442.2010.-The degree of water transport via aquaporin-2 (AQP2) water channels in renal collecting duct principal cells is reflected by the level of the urinary excretion of AQP2 (u-AQP2). In rats, the AQP2 expression varies with sodium intake. In humans, the effect of sodium intake on u-AQP2 and the underlying mechanisms have not previously been studied. We measured the effect of 4 days of high sodium (HS) intake (300 mmol sodium/day; 17.5 g salt/day) and 4 days of low sodium (LS) intake (30 mmol sodium/day; 1.8 g salt/day) on u-AQP2, fractional sodium excretion (FE Na), free water clearance (CH2O), urinary excretion of PGE 2 (u-PGE2) and cAMP (u-cAMP), and plasma concentrations of vasopressin (AVP), renin (PRC), ANG II, aldosterone (Aldo), atrial natriuretic peptide (ANP), and brain natriuretic peptide (BNP) in a randomized, crossover study of 21 healthy subjects, during 24-h urine collection and after hypertonic saline infusion. The 24-h urinary sodium excretion was significantly higher during HS intake (213 vs. 41 mmol/24 h). ANP and BNP were significantly lower and PRC, ANG II, and Aldo were significantly higher during LS intake. AVP, u-cAMP, and u-PGE 2 were similar during HS and LS intake, but u-AQP2 was significantly higher during HS intake. The increases in AVP and u-AQP2 in response to hypertonic saline infusion were similar during HS and LS intake. In conclusion, u-AQP2 was increased during HS intake, indicating that water transport via AQP2 was increased. The effect was mediated by an unknown AVP-independent mechanism. water; salt; vasopressin; aldosterone; hypertonic saline VASOPRESSIN (AVP) controls body water balance via regulation of the water permeability of the collecting duct. The aquaporin-2 water channel (AQP2), which is predominantly localized to the apical membrane and subapical vesicles of the kidney collecting duct principal cells (9, 24), plays an important role in this regulation. Short-term AVP exposure results in trafficking of subapical vesicles containing AQP2 to the apical plasma membrane, whereas long-term exposure causes a marked increase in the AQP2 whole-cell abundance via regulation of AQP2 gene transcription and AQP2 protein degradation (21, 23, 32, 44). In 1995, Kanno et al. (16) detected AQP2 in human urine. Subsequent studies in rats indicate that 3-4% of total kidney AQP2 is excreted into the urine (29, 42). Wen et al. (42) found that the AQP3 water channel, which is expressed in the basolateral membrane, was undetectable in rat urine, indicating that AQP2 excretion is not mediated by whole-cell shedding. AQP2 is associated with small vesicles, membrane fragments, and multivesicular bodies in rat urine (42), but the cellular mechanism underlying the AQP2 excretion into urine remains unknown.
VASOPRESSIN (AVP) controls body water balance via regulation of the water permeability of the collecting duct. The aquaporin-2 water channel (AQP2), which is predominantly localized to the apical membrane and subapical vesicles of the kidney collecting duct principal cells (9, 24) , plays an important role in this regulation. Short-term AVP exposure results in trafficking of subapical vesicles containing AQP2 to the apical plasma membrane, whereas long-term exposure causes a marked increase in the AQP2 whole-cell abundance via regulation of AQP2 gene transcription and AQP2 protein degradation (21, 23, 32, 44) . In 1995, Kanno et al. (16) detected AQP2 in human urine. Subsequent studies in rats indicate that 3-4% of total kidney AQP2 is excreted into the urine (29, 42) . Wen et al. (42) found that the AQP3 water channel, which is expressed in the basolateral membrane, was undetectable in rat urine, indicating that AQP2 excretion is not mediated by whole-cell shedding. AQP2 is associated with small vesicles, membrane fragments, and multivesicular bodies in rat urine (42) , but the cellular mechanism underlying the AQP2 excretion into urine remains unknown.
The urinary excretion of AQP2 (u-AQP2) has been suggested to reflect the action of AVP on the collecting duct during different physiological conditions. u-AQP2 is increased during thirsting (long-term effect of AVP stimulation) (27, 29, 33, 42) and after administration of AVP agonists (supraphysiological stimulation) (3, 16, 42) and decreased during water loading (5, 10, 28, 34) . The effects of a hypertonic challenge (short-term effect of AVP stimulation) on u-AQP2 are conflicting (4, 10, 18, 33, 27, 37) . Our group (18, 27, 37) and other investigators (10, 33) found an increase in u-AQP2 in response to a hypertonic saline infusion, while Baumgarten et al. (3) found no change in u-AQP2 despite increases in both AVP and urine osmolality (u-osm).
In addition to AVP, many other factors regulate apical AQP2 trafficking and AQP2 whole-cell abundance. Some of these factors affect the signal transduction pathways involved in AVP regulation, while others act by alternative pathways.
Using primary cultured epithelial cells from the inner medulla of rat kidneys cultured in media with different concentrations of sodium chloride for 6 days, Storm et al. (38) showed that sodium chloride-derived hypertonicity increased AQP2 mRNA and protein expression in a dose-dependent manner. Whether sodium plays a direct role in the formation of AQP2 in vivo is unknown.
The effect of sodium on AQP2 abundance and u-AQP2 has previously been examined in four in vivo studies, two studies in rats (31, 36) and two studies in humans (5, 39) . Roxas et al. (31) found a lower expression of the AQP2 transcript in Sprague-Dawley rats on a sodium-rich diet, while Song et al. (36) found a higher AQP2 protein level in rats on a sodium-rich diet despite similar AVP levels. Buemi et al. (5) found a lower u-AQP2 in humans during low mineral content water loading than during high mineral content water loading, again despite similar plasma AVP levels. Finally, Sutters et al. (39) showed that the renal sensitivity to low-dose AVP infusion is enhanced by salt restriction in healthy humans.
The objective of this investigation was therefore to study the effects of alterations in dietary sodium on 1) u-AQP2 and the underlying regulatory mechanisms at baseline and 2) the renal response to a hypertonic saline infusion in healthy humans.
We conducted a randomized, crossover study in healthy humans during baseline conditions and after hypertonic saline infusion to examine the effect of salt intake on renal handling of water and sodium. We measured the effect of high sodium (HS) intake and low sodium (LS) intake on u-AQP2, fractional sodium excretion (FE Na ), free water clearance (C H2O ), urinary excretion of PGE 2 (u-PGE 2 ), urinary excretion of cAMP (u-cAMP), and plasma concentrations of AVP, renin (PRC), ANG II, aldosterone (Aldo), atrial natriuretic peptide (ANP), and brain natriuretic peptide (BNP).
MATERIALS AND METHODS

Subjects
Inclusion criteria. Inclusion criteria were the following: 1) men and women of Caucasian descent; 2) age between 18 and 65 yr, and 3) a body mass index below or equal to 30 kg/m 2 . Exclusion criteria. Exclusion criteria were the following: 1) abnormal blood pressure, defined as a clinic blood pressure Ͼ140 mmHg systolic and 90 mmHg diastolic; 2) a medical history or clinical signs of heart, lung, liver, kidney, brain, endocrine organ, or neoplastic disease; 3) abnormal biochemical screening of the blood regarding hemoglobin, white blood cell count, platelets, sodium, potassium, creatinine, albumin, bilirubin, alanin amino transferase, alkaline phosphatase, cholesterol, and glucose; 4) abnormal urine screening for blood, albumin, and glucose; 5) abnormal electrocardiogram; 6) drug or alcohol abuse; 7) smoking; 8) medical treatment except oral hormonal contraceptives; 9) pregnancy or breast feeding; 10) blood donation Ͻ1 mo before the examination; and 11) unwillingness to use contraceptives if fertile woman.
Withdrawal criteria. Withdrawal criteria were the following: 1) lack of compliance; 2) withdrawal of consent; and 3) development of exclusion criteria during the study.
Recruitment
The subjects were recruited by advertising in public institutions and private companies in the city of Holstebro, Denmark.
Ethics and Approval
The study was approved by the local Medical Ethics Committee [JRN RRS-2006-1015-(2734-06)]. The study was conducted in conformity with the principles of the Declaration of Helsinki, and written informed consent was obtained from all subjects. The study was registered at the registration site http://www.clinicaltrials.gov (NCT00345215).
Design
We performed a randomized, crossover study. Each subject was studied on 2 separate days at least 3 wk apart. During 4 days before the study day, the subjects consumed either a HS or LS diet in randomized order. A computer-generated randomization list was drawn up by an independent colleague. A copy of the list was given to the hospital kitchen, and the original was kept in a sealed envelope at the department. The code was revealed when the study was finished.
Effect Variables
The primary effect variable was u-AQP2, and the secondary effect variables were urinary sodium excretion rate (U Na), FENa, urine volume (V), CH20, serum osmolality (s-osm), u-osm, u-cAMP, and u-PGE2; plasma concentrations of AVP, PRC, ANG II, Aldo, ANP, BNP, sodium (p-Na), and albumin (p-albumin); systolic and diastolic blood pressure; and heart rate, body weight, and glomerular filtration rate (GFR).
Number of Subjects
A difference in u-AQP2 of 0.25 ng/min between HS and LS intake was considered the minimal relevant difference based on interventions in previous pilot experiments. A sample size of 21 subjects who could be evaluated had 90% power to detect this difference assuming a level of significance of 5% and a standard deviation of 0.24 ng/min. Because a few subjects were expected to drop out, 25 subjects were included.
Experimental Procedure Before the Study Day
Five days before the study day, the subjects collected a standardized HS (ϳ300 mmol sodium/day; 17.5 g salt/day), or LS (ϳ30 mmol sodium/day; 1.8 g salt/day) 4-day diet from the hospital kitchen. Depending on the individually estimated energy requirement, the participants were given either a diet of 8,000 or 11,000 kJ/day. The energy distribution was 55% carbohydrates, 15% proteins, and 30% lipids. The 4-day diet was started the following morning.
Fluid intake was also standardized during the 4 days. The subjects were asked to drink exactly 250 ml·1,000 kJ Ϫ1 ·day Ϫ1 and to abstain from coffee, tea, and alcoholic beverages.
The subjects were instructed to keep their physical activity unchanged during the two experiments and to abstain from hard training.
The subjects collected their urine for 24 h the day before the study day.
Experimental Procedure on the Study Day
On the study day, the subjects were asked to drink 175 ml of water every 30 min from 7:00 AM. The subjects arrived at the department at 8:00 AM. Peripheral intravenous lines were inserted into the antecubital veins of both forearms, one for infusion of 51 Cr-EDTA and hypertonic saline, and one for withdrawal of blood samples. The subjects were kept in the supine position from 8:00 AM to 1:30 PM except during voiding, which took place in the sitting or standing position.
At 8:30 AM, a priming dose of 51 Cr-EDTA was administered, followed by sustained infusion. After 60 min of equilibration, the study continued with five clearance periods, the first two of 30-min duration (P1-P2), the last three of 60-min duration (P3-P5). The first two clearance periods were baseline periods.
At 10:30 AM, 7 ml/kg of 3% saline were given over 30 min. Blood pressure and heart rate were measured every 30 min from 9:30 AM to 1:30 PM.
Urine was collected in each clearance period and analyzed for sodium, osmolality, u-AQP2, u-cAMP, u-PGE 2, and 51 Cr-EDTA. Blood samples were drawn every 30 min from 9:30 AM to 10.30 AM and every hour from 11:30 AM to 1:30 PM and were analyzed for sodium, osmolality, and 51 Cr-EDTA. In addition, analysis of AVP, PRC, ANG II, Aldo, ANP, and BNP were performed from blood samples drawn at 10:30 AM, 11:30 AM, 12:30 PM, and 1:30 PM.
Methods
All blood samples were centrifuged for 15 min at 3,000 rpm at 4°C. Plasma was separated from blood cells and kept frozen at Ϫ20°C until assayed. ANP in plasma was determined by radioimmunoassay (RIA), as previously described (26) . ANP was extracted from plasma with a C 18 September-Pack (Water Associates, Milford, MA) using ethanol, acetic acid, and water. For RIA, rabbit anti-ANP antibody was obtained from the Department of Clinical Chemistry, Bispebjerg Hospital (Copenhagen, Denmark). The minimal detection concentration was 0.5 pmol/l. The coefficients of variation were 12% (interassay) and 10% (intra-assay). BNP in plasma was determined by RIA as previously described (15) . Immunoreactive BNP was extracted from plasma with a C 18 September-Pack (Water Associates) eluted by 80% ethanol in a 4% acetic acid solution. A rabbit anti-BNP antibody without cross-reactivity with urodilatin or ␣-ANP was developed in our laboratory. The minimal detection concentration was 0.5 pmol/l. The coefficients of variation were 11% (interassay) and 6% (intraassay). AVP in plasma was measured by RIA using a modification of the method described previously (25) . AVP was extracted from plasma with a C18 September-Pack (Water Associates). The antibody against AVP was a gift from Professor Jacques Dürr (Miami, FL). The minimal detection concentration was 0.5 pmol/l. The coefficients of variation were 13% (interassay) and 9% (intra-assay). ANG II in plasma was determined by RIA using a modification (26) of the method originally described (17) . ANG II was extracted from plasma with a C18 September-Pack (Water Associates). The antibody against ANG II was obtained from the Department of Clinical Physiology, Glostrup Hospital (Glostrup, Denmark). The minimal detection concentration was 2 pmol/l. The coefficients of variation were 12% (interassay) and 8% (intra-assay). Aldo was determined by RIA using a commercial kit (Diagnostic Systems Laboratories, Webster, TX). The minimal detection concentration was 22 pmol/l. The coefficients of variation were 8.2% (interassay) and 3.9% (intra-assay). PRC was also determined by a commercial RIA (CIS Bio International, Gifsur-Yvette Cedex, France). The minimal detection concentration was 0.5 pg/ml. The coefficients of variation were 14.5% (interassay) and 4.5% (intra-assay).
Urine samples were centrifuged for 5 min at 3,000 rpm, and 125-1,000 l of the supernatant was freeze dried and kept frozen at Ϫ20°C for 2-8 mo until assayed. We have done pilot experiments to ensure that the concentration of the effect variables in the urine does not decrease over time. The experiments showed that the effect variables are stable at Ϫ20°C for 2 yr. u-AQP2 was measured by a RIA as previously described (27) . The anti-AQP2 antibody (LL127) for RIA was obtained from Søren Nielsen (The Water and Salt Research Center, Institute of Anatomy, Aarhus University, Aarhus, Denmark). The antibody was raised in rabbits. The epitope amino acid sequence for generation of the LL127 antibody was NH2-CELH-SPQSLPRGSKA-COOH (24) . The minimal detection concentration was 32 pg/tube. The coefficients of variation were 11.7% (interassay) and 5.9% (intra-assay). Dotblotting (data not shown) with a number of AQP2 peptides/AQP2 phospopeptides (unphosphorylated AQP2 peptide, pAQP2-256, pAQP2-261, pAQP2 264/269, and pAQP2 261/ 264) was performed to study whether the antibody recognized phosphorylated AQP2. The phosphopeptides used for single or combination of phosphorylation had the same backbone and were phosphorylated at different serine residues: NH2-WEEREVRRRQS(256)VELHS(261) PQS(264)LPRGS(269)KA-COOH. The dotblotting confirmed that the anti-AQP2 antibody recognized all phospho forms except the pS269 peptide, similar to a number of AQP2 antibodies previously characterized by dotblotting (14) (The experiment was performed at the Water and Salt Center, University of Aarhus). u-cAMP was measured by RIA using a commercial kit (Biomedical Technologies, Stoughton, MA). The minimal detection concentration was 0.05 pmol/l. The coefficients of variation were 8% (interassay) and 3% (intra-assay). u-PGE2 was measured by RIA using a commercial kit (Assay Designs, Ann Arbor, MI). The minimal detection concentration was 8.26 pg/ml. The coefficients of variation were 10.9% (interassay) and 6.3% (intra-assay).
s-osm and u-osm were measured by freezing-point depression (Advanced model 3900 multisampling osmometer).
C H2O was determined according to the formula CH2O ϭ V Ϫ Cosm, where V is urine output, and Cosm is osmolality clearance.
Urine was screened for blood, albumin, and glucose with standard urine test strips. Plasma and urinary concentrations of sodium and creatinine were determined at the Department of Clinical Biochemistry, Holstebro Hospital (Holstebro, Denmark) using conventional methods. All clearances were standardized to a body surface area of 1.73 m 2 . GFR was measured using the constant infusion clearance technique with 51 Cr-EDTA as reference. Blood pressure was measured with a UA-743 digital blood pressure meter (A&D, Tokyo, Japan).
Statistics
Statistical analyses were performed using SPSS version 15 (SPSS, Chicago, IL).
Single baseline values were obtained by taking the weighted average of the measurements from the two baseline periods. The baseline values during HS and LS intake were compared by paired samples t-tests.
We used the General Linear Model Repeated Measures procedure in SPSS with salt intake and time as within-subject factors to compare the effect of HS and LS intake.
The changes in response to the hypertonic saline infusion in each group were analyzed with the General Linear Model Repeated Measures procedure with time as a within-subject factor and paired samples t-tests with Bonferroni correction as post hoc tests.
The changes in response to the hypertonic saline infusion during HS and LS intake were compared with the General Linear Model Repeated Measures procedure with salt intake and time as withinsubject factors and paired samples t-tests with Bonferroni correction as post hoc tests.
P values Ͻ0.05 were considered significant. Variables are normally distributed and presented as means with SD or 95% confidence intervals, if not otherwise stated.
RESULTS
Demographics
Twenty-five healthy subjects were enrolled in the study. Four were withdrawn from the study, one because of lack of compliance, two because of failure to obtain intravenous access, and one because of withdrawal of consent. Twenty-one subjects completed the study [age: 26 yr (SD 4); men: n ϭ 10; women: n ϭ 11; BMI: 25.4 kg/m 2 (SD 2.8)]. All had normal office blood pressures [systolic blood pressure: 124 mmHg (SD 10); diastolic blood pressure: 76 mmHg (SD 6)].
Twenty-Four-Hour Urine Collection
The 24-h U Na was significantly lower during LS intake than during HS intake [41 mmol (SD 29) vs. 213 mmol (SD 66), P Ͻ 0.001], indicating that the subjects had kept the supplied diets. The u-osm was significantly lower during LS intake compared with HS intake [267 mosmol/kgH 2 O (SD 15) vs. 470 (SD 37) mosmol/kgH 2 O; P Ͻ 0.001]. The 24-h V did not differ between HS intake and LS intake [2,482 ml (SD 898) vs. 2,654 ml (SD 649); P ϭ 0.409], but the u-AQP2 was significantly higher during HS intake compared with LS intake [1.42 ng/min (SD 0.30) vs. 1.10 ng/min (SD 0.23); P Ͻ 0.001].
Effects of Sodium Diet at Baseline
Sodium excretion. U Na was 81% lower (P Ͻ 0.001) and FE Na was 80% lower (P Ͻ 0.001) during LS intake compared with HS intake in the baseline clearance periods (Table 1) .
Water excretion, u-AQP2, u-osm, u-cAMP, and u-PGE 2 . V, C H2O , u-cAMP, and u-PGE 2 were not affected by the sodium intake at baseline (Table 1) . u-AQP2 was significantly lower during LS intake compared with HS intake at baseline (31%, P Ͻ 0.001) ( Table 1) . u-AQP2 corrected for creatinine excretion (u-AQP2 CR ) was also significantly lower (31%, P Ͻ 0.001) during LS intake compared with HS intake at baseline (Table 1) .
U-osm was significantly lower during LS intake at baseline (P ϭ 0.018) ( Table 1) .
Vasoactive hormones.
The plasma level of AVP was not affected by the sodium intake at baseline [HS vs. LS: 0.85 pg/ml (SD 0.05) vs. 0.83 pg/ml (SD 0.05); P ϭ 0.699] (Fig. 1B) . Table 2 shows PRC, ANG II, Aldo, ANP, and BNP at baseline and after the hypertonic saline infusion. Significantly higher plasma concentrations of PRC, ANG II, and Aldo were seen during LS intake at baseline. PRC was 245% higher (P ϭ 0.016), ANG II 102% higher (P Ͻ 0.001), and Aldo 159% higher (P Ͻ 0.001) during LS intake compared with HS intake at baseline. Values are means with 95% confidence intervals in parentheses. UNa, urinary sodium excretion rate; FENa, fractional sodium excretion; V, urinary flow; CH2O, free water clearance; u-AQP2, urinary aquaporin-2 (AQP2) excretion rate; u-AQP2CR, urinary AQP2 excretion corrected for creatinine; u-osm, urine osmolality; u-cAMP, urinary cAMP excretion; u-PGE2, urinary PGE2 excretion; s-osm, serum osmolality; p-Na, plasma sodium concentration; PGLM RM, high salt (HS) compared with low salt (LS), General Linear Model (GLM) repeated measures (RM) with salt intake and time as within-subject factors. *P Ͻ 0.001, †P Ͻ 0.01, ‡P Ͻ 0.05 HS compared with LS, paired samples t-test. §P Ͻ 0.05 compared with baseline, paired samples t-test with Bonferroni correction.
In addition, LS balance was accompanied by significantly lower natriuretic peptide levels ( Table 2) . ANP was 26% lower (P Ͻ 0.001) and BNP was 46% lower (P ϭ 0.002) during LS intake compared with HS intake at baseline.
Blood pressure, heart rate, s-osm, body weight, p-Na, and p-albumin. The absolute values of the systolic and diastolic blood pressure and the heart rate during HS and LS intake before and after the hypertonic saline infusion are presented in Table 3 . No difference was found in systolic or diastolic blood pressure or in heart rate between HS and LS intake at baseline (Table 3) .
s-osm was significantly lower during LS intake (Table 1) , and body weight was significantly lower during LS intake compared with HS intake at baseline [77.0 kg (SD 12.9) vs. 77.8 (SD 12.6); P ϭ 0.005].
p-Na was significantly lower during LS intake compared with HS intake at baseline (P Ͻ 0.001) ( Table 1) .
p-Albumin was significantly higher during LS intake compared with HS intake at baseline [42.8 g/l (SD 2.8) vs. 41.4 g/l (SD 2.4); P Ͻ 0.001].
GFR. GFR was significantly higher during HS intake compared with LS intake at baseline (P ϭ 0.004) ( Table 3) .
Effect of Hypertonic Saline Infusion
Sodium excretion. The absolute values of U Na and FE Na before and after the hypertonic saline infusion are given in Table 1 . The relative changes in response to the hypertonic saline infusion during HS and LS intake are listed in Table 4 . The hypertonic saline infusion was accompanied by a significant increase in U Na and FE Na on both study days, lasting throughout the experiment with a maximum 180 min after infusion start ( Table 1 ). The relative increases in both U Na and FE Na in response to the hypertonic saline infusion were significantly higher during LS intake compared with HS intake throughout the experiment (Table 4) .
Water excretion, u-AQP2, u-osm, u-cAMP, and u-PGE 2 . The absolute values of V, C H2O , u-AQP2, u-AQP2 CR , u-osm, u-cAMP, and u-PGE 2 before and after the hypertonic saline infusion are shown in Table 1 . The changes in response to the hypertonic saline infusion during HS and LS intake are listed in Table 4 .
During both diets, the hypertonic saline infusion induced a significant and sustained decrease in V with a maximum 120 min after infusion start ( Table 1 ). The relative decreases in urinary flow did not differ between the two study days (Table 4) .
C H2O decreased significantly after the hypertonic saline infusion during both diets with a maximum after 120 min (Table 1) . C H2O changed from positive values at baseline to negative values after infusion, indicating a change from water excretion to water reabsorption. The relative decreases in C H2O were more pronounced during HS intake, but the difference in the relative change between HS and LS intake was significant only 120 min after infusion start (Table 4) . u-AQP2 increased significantly in response to the hypertonic saline infusion during both diets ( Table 1 ). The increase reached maximum 120 min after the infusion start during HS intake and 1 h later during LS intake. The relative increases did not differ between the two diets throughout the experiment (Table 4) . u-AQP2 CR followed the same pattern ( Table 4) . The increases in u-osm in response to the hypertonic saline infusion were similar during HS and LS intake (Table 4 ). Figure 2 shows the effect of the hypertonic saline infusion on u-AQP2 CR and u-osm during HS intake and LS intake. The increase in u-osm was more prompt compared with the increase in u-AQP2 CR during both diets.
u-cAMP was not affected by the hypertonic saline infusion during the two diets (HS: P ϭ 0.197; LS: P ϭ 0.218).
u-PGE 2 decreased in response to the saline infusion during both diets (Table 1) , with a nadir 180 min after infusion start during HS intake and 1 h earlier during LS intake. The relative decreases in u-PGE 2 were not significantly different between the two diets ( Table 4) . Vasoactive hormones. The absolute values of PRC, ANG II, Aldo, ANP, and BNP before and after the hypertonic saline infusion are shown in Table 2 , while the absolute values of AVP are depicted in Fig. 1B . The relative changes in response to the hypertonic saline infusion during HS and LS intake are listed in Table 5 .
AVP increased significantly after the saline infusion during both diets (Fig. 1B) . The increases followed the same pattern during the two diets with a maximum after 60 min ( Table 5 ). The relative changes in AVP were not significantly different between HS and LS intake throughout the study day (Table 5) .
PRC tended to decrease during both diets in response to the hypertonic saline infusion, but the changes from baseline were not significant ( Table 2 ). The relative decreases in PRC were significantly larger during LS intake (Table 5) . ANG II and Aldo decreased significantly in response to the hypertonic saline infusion during both diets (Table 2) , ANG II with a maximum after 180 min and Aldo with a maximum after 120 min. The relative decreases in ANG II and Aldo were significantly larger during LS intake ( Table 5) .
The hypertonic saline infusion induced a significant and sustained increase in ANP on both study days ( Table 2 ). The relative increase in ANP was significantly higher during LS intake (Table 5) .
BNP increased significantly 120 min after infusion start during HS intake and 180 min after infusion start during LS intake. The relative increases did not differ between the two study days throughout the experiment (Table 5) .
Blood pressure, heart rate, s-osm, body weight, p-Na, and p-albumin. Systolic blood pressure increased in response to the hypertonic saline during HS, but did not change during LS intake (Table 3) .
Hypertonic saline induced a significant decrease in diastolic blood pressure during LS intake (P Ͻ 0.001), but did not affect the diastolic blood pressure during HS intake ( Table 3) .
The heart rate increased significantly in response to the saline infusion with a maximum 120 min after infusion start during both diets. Throughout the study day, there was no significant difference between the relative increases in heart rate between the two diets (P ϭ 0.401).
The increase in s-osm in response to the hypertonic saline infusion was significantly higher during LS intake (Table 4) .
Body weight did not change in response to the hypertonic saline infusion during HS intake, but increased during LS intake from 77.0 kg (SD 12.9) at baseline to 77.7 kg (SD 13.0) at the end of the study day. The increase was statistically significant [0.7 kg (SD 0.3); P Ͻ 0.001].
p-Na increased in response to the hypertonic saline infusion during both diets with a maximum after 60 min ( Table 1) . The relative increases were significantly higher during LS intake compared with during HS intake ( Table 4) .
p-Albumin fell in response to the hypertonic saline infusion during both diets to comparable levels at the end of the study days [HS vs. LS: 37.7 g/l (SD 2.5) vs. 37.7 g/l (SD 2.4); P ϭ 0.867].
GFR. The hypertonic saline infusion decreased GFR with a maximum 60 min after infusion start ( Table 3) . The difference in the reductions in GFR between the two diets was not statistically significant (P ϭ 0.688).
Correlations
At baseline, Aldo was not correlated with u-AQP2, u-AQP2 CR , U Na , or FE Na ; ANG II was not correlated with u-AQP2 or u-AQP2 CR ; and u-AQP2 was not correlated with u-AQP2 CR during any of the diets. ANP was significantly correlated with u-AQP2 CR (r ϭ 0.520, P ϭ 0.008), U Na (r ϭ 0.552, P ϭ 0.005), and FE Na (r ϭ 0.527, P ϭ 0.007) during HS intake at baseline. Values are means with 95% confidence intervals in parentheses except the relative changes in UNa and FENa which are given as medians with quartiles in parentheses because of lack of normality. *P Ͻ 0.001, †P Ͻ 0.01, ‡P Ͻ 0.05 HS compared with LS, paired samples t-test with Bonferroni correction or Wilcoxon signed ranks test (UNa and FENa).
The decrease in Aldo in response to the saline infusion was significantly correlated with the increase in U Na during both diets (Fig. 3) . Similarly, the increase in ANP was significantly correlated with the increase in U Na in response to the saline infusion during both diets (Fig. 4) . The increase in u-AQP2 in response to the saline infusion was significantly correlated with the decrease in Aldo during both diets (Fig. 5) . The increase in u-AQP2 CR was also significantly correlated with the decrease in Aldo after the hypertonic saline infusion during both diets (HS: r ϭ Ϫ0.569, P ϭ 0.004; LS: r ϭ Ϫ0.601, P ϭ 0.003). There was no correlation between 1) the increase in u-AQP2 and the increase in ANP, 2) the increase in u-AQP2 CR and the increase in ANP, 3) the increase in u-AQP2 and the decrease in ANG II, and 4) the increase in u-AQP2 CR and the decrease in ANG II in response to the hypertonic saline infusion during any of the diets.
DISCUSSION
The aim of the present study was to examine the effect of sodium intake on u-AQP2 and to identify potential, regulatory mechanisms.
Higher u-AQP2 During HS Intake Than During LS Intake
We found higher u-AQP2 and u-AQP2 CR during HS intake than during LS intake in healthy subjects. To our knowledge, u-AQP2 has not previously been studied in humans during HS and LS intake in a crossover study. Buemi et al. (5) found a higher u-AQP2 during assumption of water with high mineral content compared with water with low mineral content in healthy humans, which is in agreement with our results. However, the potassium and calcium content did also vary between the mineral waters and could have contributed to the difference in u-AQP2. In rats, Roxas et al. (31) reported a fivefold lower expression of the AQP2 transcript during HS intake compared with normal sodium intake, while Song et al. (36) described a higher expression of the AQP2 protein during HS intake. The apparent discrepancy between these two studies could simply reflect that there are different ways of regulation of u-AQP2 independent of AQP2 production rate, e.g., regulation of AQP2 protein degradation. 
Comparable Diuresis During HS and LS Intake
In the present study, the subjects were relatively dehydrated during LS intake. This was evident by the lower body weight, the higher p-albumin, the lower U Na , the lower FE Na , and the lower p-Na during LS intake compared with the values during HS intake. The lower U Na during LS intake is caused partly by a decreased filtration of sodium (caused by the lower p-Na and GFR), partly by an increased tubular reabsorption of sodium. The increased tubular reabsorption of sodium could be attributed to the increase in Aldo during LS intake, which most likely was stimulated as a compensatory phenomenon to avoid or reduce volume depletion. During this condition, urine volume is expected to decrease. Instead, we found similar 24-h urine volumes during HS and LS intake. The underlying mechanism is not clear, but reduced water permeability of the principal cells during LS intake could play a role.
It should be emphasized that the results of the present study are obtained during water diuresis and not during a normal physiological diuresis. The low u-osm and the positive C H2O values at baseline reflect this. u-AQP2 is known to be reduced during water diuresis with a nadir after 60 -90 min (34) . Our subjects received a continuous water load throughout the study day to avoid fluctuations in the waterload-induced reduction in u-AQP2.
It is probable that AQP2 has a diurnal excretion rhythm that follows the diurnal rhythm of AVP. However, it has been reported that the AVP level peaks at 4 AM and remains steady during the day (30) . Therefore, we do not believe that the diurnal rhythm of AVP has an effect on our results.
Comparable Increases in u-AQP2 in Response to Hypertonic Saline Infusion During HS and LS Intake
The infusion of hypertonic saline allows the analysis of short-term effects of AVP stimulation, triggered by the rise in serum osmolarity. u-AQP2 and u-AQP2 CR increased significantly during both diets in response to the hypertonic saline infusion. Our group (18, 27, 37) and other investigators (10, 33) have previously found an increase in AVP, u-AQP2, and u-osm in response to a hypertonic challenge, while Baumgarten et al. (3) surprisingly found no change in u-AQP2 despite Fig. 3 . Correlation between the changes in plasma concentration of aldosterone (Aldo) and the change in urinary sodium excretion rate (UNa) from baseline to 60 min after saline infusion start during HS intake (A) and LS intake (B) in 21 healthy individuals. A: 1 data point (Ϫ83 pmol/l, 0.04 ìmol/min) is superimposed on another (Ϫ82 pmol/l, 0.05 ìmol/min). Fig. 4 . Correlation between the change in plasma concentration of atrial natriuretic peptide (ANP) and the change in UNa from baseline to 60 min after saline infusion start during HS intake (A) and LS intake (B) in 21 healthy individuals.
increases in both AVP and u-osm. We believe that the conflicting results reflect differences in study design. The oral water intake before and during the hypertonic saline infusion test was almost three times higher in the study by Baumgarten et al. compared with ours. It is well known that water loading decreases u-AQP2. Thus perhaps the stimulatory effect of the hypertonic saline was overcome by the stronger inhibitory effect of the massive water load on u-AQP2 in the study by Baumgarten et al. The fact that the u-AQP2 preinfusion level was almost zero in the study by Baumgarten et al. supports this explanation.
The different antibodies used in the two studies could have played a role. The antibody used in our study recognizes phosphorylated AQP2 except when phosphorylated at Ser269, similar to a number of AQP2 antibodies previously characterized by dotblotting (14) .
We found no difference in the decrease in V, the increase in u-AQP2, or the increase in u-AQP2 CR in response to the hypertonic saline infusion between HS intake and LS intake. The antidiuretic response to hypertonic saline during HS and LS intake is consistent with results obtained from similar studies in dogs, humans, or rats (8, 11, 22) . However, another group found an increased concentration ability during HS intake, but a paradoxical decreased diuretic response to a hypertonic saline infusion during HS intake (4).
In our study, the rise in u-osm in response to the hypertonic saline infusion was already significant 60 min after the infusion start, despite that the rise in u-AQP2 was not significant until 120 min after the infusion start (Fig. 2) . A possible explanation for the delay in the AQP2 rise compared with the rise in u-osm could be that it takes longer time to excrete AQP2 into the urine than to insert AQP2 in the apical membrane.
Potential Regulatory Mechanisms Underlying Increased u-AQP2 During HS Intake
We found similar AVP and u-cAMP levels during HS and LS intake despite the higher u-AQP2 during HS intake at baseline. This has previously been reported in rats (36) . The finding indicates either that the renal sensitivity to the antidiuretic effect of AVP is increased during HS intake or that u-AQP2 is regulated by an AVP-independent mechanism.
The hypertonic saline infusion caused comparable relative increases in AVP, u-AQP2, and u-AQP2 CR during HS and LS intake, which speaks against an increased sensitivity to AVP during HS intake. Thus it seems that other factors than AVP are responsible for the increased u-AQP2 during HS intake.
We found a significant correlation between ANP and u-AQP2 CR during HS intake at baseline. In rats, ANP infusion caused a marked increase in the apical targeting of AQP2 after 90 min (41) . The increase was regarded as either a direct or a compensatory effect to increase water reabsorption. A human study with head-out water immersion, which causes an expansion of central vascular volume without affecting plasma composition, demonstrated increased u-AQP2 accompanied by a decrease in AVP and an increase in ANP (6) . Thus the increase in u-AQP2 during HS intake in our study may be due to an increased apical trafficking of AQP2 caused by the increase in ANP, even though we cannot prove a causal relationship.
The effect of BNP on the regulation of AQP2 during salt adaptation has to our knowledge not previously been addressed. Alternatively, the increased u-AQP2 during HS intake could be due to a higher AQP2 transcription caused by the hypertonic stress in the inner medulla during HS intake. This is suggested from studies of AQP2 transcription in cell culture models (12, 20, 38) .
Lower u-AQP2 During LS Intake Could be a Compensatory Effect in Response to Extracellular Fluid Volume Depletion
We measured significantly higher plasma levels of PRC, ANG II, and Aldo during LS intake compared with HS intake. We regard these hormonal changes as compensating mechanisms during the extracellular fluid volume depletion present during LS intake.
Besides its major role in controlling the transcription and the apical translocation of ENaC, Aldo also regulates the abundance and apical trafficking of AQP2 (7, 10) . Thus the increased level of Aldo found during LS intake in our study may have contributed to the decreased level of u-AQP2 found during LS intake via regulation of the abundance of AQP2. Future studies with administration of Aldo antagonists to Fig. 5 . Correlation between the change in u-AQP2 and the change in plasma Aldo concentration from baseline to 60 min after saline infusion start during HS intake (A) and LS intake (B) in 21 healthy individuals. B: 1 data point (Ϫ39 pmol/l, Ϫ0.03 ng/min) is superimposed on another (Ϫ41 pmol/l, Ϫ0.03 ng/min). subjects on sodium-restricted and sodium-enriched diets will clarify whether a causal relationship exists between Aldo and u-AQP2.
Alternatively, the decreased u-AQP2 during LS intake could reflect a decreased transcription of the AQP2 gene caused by the sustained hypotonicity present during LS intake. Saito et al. (35) have shown a reduction in murine AQP2 promoter activity by hypotonicity.
Potential Mechanisms Underlying Increased Natriuretic Response to Hypertonic Saline Infusion During LS Intake
The relative increases in U Na and FE Na in response to the hypertonic saline infusion were higher during LS intake ( Table 4) .
The larger decrease in ANG II and Aldo after the hypertonic saline infusion during LS intake compared with during HS intake may at least in part explain the larger increase in the natriuresis in response to the hypertonic saline during LS intake.
The increase in ANP in response to the saline infusion was significantly correlated with the increase in U Na and FE Na during both diets. The larger increase in ANP in response to the hypertonic saline during LS intake may be responsible for the increased natriuretic response during LS intake.
The larger increase in p-Na in response to the saline infusion during LS intake is perhaps also involved. An increase in p-Na may contribute to the natriuretic response of salt loading by a mechanism independent of the concomitant increase in extracellular fluid volume (1).
The diastolic blood pressure decreased significantly in response to the hypertonic saline infusion during LS intake. We cannot explain this finding. We speculate that the decrease, although significant, could be by chance.
In conclusion, u-AQP2 was higher during HS intake than during LS intake, and the responsible mechanism was AVP independent. We found a significant correlation between ANP and u-AQP2 during HS intake. ANP, Aldo, and tonicity may be involved in the regulation of u-AQP2 during HS and LS intake. Further studies are required to improve our understanding of the roles of ANP, Aldo, and tonicity in the regulation of u-AQP2 during salt adaptation.
We found comparable significant increases in AVP, ucAMP, and u-AQP2 in response to the hypertonic saline infusion during HS and LS intake, but a larger natriuretic response to the hypertonic saline infusion during LS intake. We suggest that the larger natriuretic response is mediated in part by the larger increase in the filtered sodium load and in part by the larger decrease in Aldo and the larger increase in ANP during LS intake.
